2025 ABSTRACT SUBMISSIONS

Abstract submission for the 2025 meeting closed on November 3, 2024. Submission notifications will be sent in late December.

Please note – you will not be able to access your submitted abstract while it is in the review process.

Revisions to the Abstract Submission, including the Author Listing, Title, Body and Figures, are not permitted once the submission deadline has passed. The Abstract will be included in the Annual Meeting materials exactly as submitted.

Late-Breaking Abstract Submission

Late-Breaking Abstract Submission is now open. The late-breaking submission deadline is December 8, 2024. There will be no exceptions for submissions after this date.

Late-breaking abstract submission is intended for abstracts with late-breaking data that was not known or fully available by the original submission deadline. The Late-breaking Abstract deadline is not intended for abstracts to be submitted “late” or to be an extension of the general submission deadline. Late-breaking abstracts should present data that are high impact, ground breaking, innovative, and of high scientific significance to the specialty. Medically challenging cases are not accepted for late-breaking submission.

For late-breaking abstracts, authors need to justify why the abstract is considered late-breaking during submission.

Late-breaking abstracts will be considered for in-person poster presentation during the meeting only; they are not eligible for oral presentation.

Submit a Late Breaking Abstract

LATE-BREAKING SUBMISSION GUIDELINES

When preparing your abstracts, please review the complete Submission Guidelines.

Medically challenging cases are not accepted. Late-breaking abstract submissions will be considered for in person poster presentations only. Late-breaking abstracts are not eligible for abstract awards.

As noted during abstract submission, the author that was designated during the submission process as the Presenting Author will be the first author in the final author listing. Should you change the presenting author for the meeting, we are unable to change the author listing and it will be published as it was submitted.

Late-Breaking Submission Rules

Medically Challenging Cases are not eligible for late-breaking submission.
Authors must justify why the abstract is considered late-breaking.
Revisions are not allowed after the submission deadline. The abstract will be listed in all program materials as submitted.
There are no restrictions on the number of submissions per submitter.
The abstract text must be in English.
The Introduction, Methods, Results and Conclusions sections cannot exceed 4500 characters (including spaces) combined. Each section cannot exceed 2500 characters (including spaces).
Brand Names are prohibited. Please use the generic name.
Abstract reviews are blinded. Do not include the institution in the abstract body or title.
Research presented at the Annual Meeting should not be published in an indexed journal prior to the 2025 Annual Meeting.

Human Subjects

Human subjects should not be identifiable. Do not disclose patients’ names, initials, hospital numbers, dates of birth, or other protected health care information.
Please review the WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.
Retain copies of the IRB approval and documentation of written informed consent from each study subject.
Please review the US Department of Health & Human Services Guidelines: https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html#standard.

Animal Subjects

Research performed in vertebrate animals must explicitly state that the study was approved by the authors’ IRB for animal research (e.g., the Institutional Animal Care and Use Committee).
Please review the US Public Health Service Policy on Humane Care and Use of Laboratory Animals: https://olaw.nih.gov/policies-laws/phs-policy.htm.

Submission Best Practices

Originality and Scientific Merit: Were novel concepts or approaches used? Does the abstract challenge existing paradigms or develop new methodologies or technologies? Does the abstract address an important problem? Was scientific knowledge advanced?
Quality and Integrity of Research Design and Data Analysis: Is the study design clearly described? Are issues of reliability and validity of the measures addressed? Are the statistical analyses appropriate?
Conclusions: Are conclusions clearly stated? How well are the conclusions justified by the data?
Technical Writing: Is the abstract clearly written and well-organized, or is the abstract difficult to follow and unfocused? Are there virtually no spelling, punctuation, or grammatical errors, or do the errors pose a distraction to the content provided in the abstract submission?